EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ABO ‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

Franziska Certa, Peter A Horn, Julius Keyl, Bastian Mende, Smiths Lueong, Thomas Hilser, Sarah Theurer, Isabel Virchow, Yasmin Zaun, Michael Pogorzelski, Martin Metzenmacher iD, Halime Kalkavan und 4 weitere

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Franziska Certa und 15 weiteren Autor:innen. Beteiligte Einrichtung: West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ABO Blood-Group System, Antibodies, Monoclonal, Humanized, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Fakultät, Universität Duisburg-Essen Advanced Clinician Scientist Programm UMEA, Bundesministerium für Bildung und Forschung, Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In patients with metastatic non‐small cell lung cancer (NSCLC) with high programmed death‐ligand 1 (PD‐L1) expression, there is still a lack of biomarkers to identify patients with maximum benefit from first‐line treatment with checkpoint inhibitor therapy (CIT) alone. This work examines the impact of different ABO blood groups (BG) on the response to CIT monotherapy.

Methods

Retrospective analysis of patients with stage IV NSCLC and high PD‐L1 expression (tumor proportional score/TPS ≥ 50%), receiving first‐line therapy with pembrolizumab alone or in combination with chemotherapy at the West German Cancer Center from 2017 to 2022. Study endpoints were overall survival (OS) and progression‐free survival (PFS).

Results

Eighty‐two patients were included in the analysis. Twenty‐two patients (27%) received first‐line therapy with pembrolizumab alone (monoimmunotherapy cohort/MIC), of which seven patients (32%) had BGO. Sixty patients (73%) were treated with pembrolizumab combined with platinum‐based chemotherapy (chemoimmunotherapy cohort/CIC), of which 38 (63%) had BGO. In MIC, younger age and BGO were independent predictors of favorable OS (BGO vs. other ABO‐BG: HR 0.22, 95% CI: 0.1–0.9; p = 0.037; median OS 62 versus 19 months) and PFS (BGO vs. other ABO‐BG: HR 0.21, 95% CI: 0.1–0.8; p = 0.024; median PFS 39 vs. 4 months). There was no significant impact of ABO‐BG in patients treated with CIC. In support, a historical control group treated with chemotherapy alone also showed no prognostic impact of the ABO‐BG.

Conclusion

BGO associates with favorable survival in patients with NSCLC receiving pembrolizumab monotherapy, but not in patients with chemo‐immunotherapy or chemotherapy. Further validation of this promising strategy for personalized decision‐making is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungABO Blood-Group SystemAntibodies, Monoclonal, HumanizedLung NeoplasmsAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAged, 80 and overAdultPrognosis

Stichwörter der Autor:innen

blood groupcheckpoint inhibitornon‐small cell lung cancerpredictive biomarkers

Substanzen

pembrolizumabABO Blood-Group SystemAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany.
  • Medical Faculty, University Duisburg-Essen, Essen, Germany.
  • Institute for Transfusion Medicine, University Hospital of Essen, Essen, Germany.
  • West German Cancer Center, Institute of Pathology Essen, University Hospital Essen, Essen, Germany.
  • Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany.
  • Central Pharmacy, University Hospital Essen, Essen, Germany.

ORCID-Profile: Martin Metzenmacher, Gregor Zaun

Förderung

  • Medizinische Fakultät, Universität Duisburg-Essen Advanced Clinician Scientist Programm UMEA
  • Bundesministerium für Bildung und Forschung
  • Deutsche Krebshilfe
  • Deutsche Forschungsgemeinschaft
  • Medizinische Fakultät, Universität Duisburg-Essen

Zitieren

APA

Certa, F., Horn, P. A., Keyl, J., Mende, B., Lueong, S., Hilser, T., Theurer, S., Virchow, I., Zaun, Y., Pogorzelski, M., Metzenmacher, M., Kalkavan, H., Kasper, S., Schuler, M., Wiesweg, M., & Zaun, G. (2025). ABO ‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70037

Vancouver

Certa F, Horn PA, Keyl J, Mende B, Lueong S, Hilser T, et al. ABO ‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70037

BibTeX
@article{Certa2025,
  author = {Certa, Franziska and Horn, Peter A and Keyl, Julius and Mende, Bastian and Lueong, Smiths and Hilser, Thomas and Theurer, Sarah and Virchow, Isabel and Zaun, Yasmin and Pogorzelski, Michael and Metzenmacher, Martin and Kalkavan, Halime and Kasper, Stefan and Schuler, Martin and Wiesweg, Marcel and Zaun, Gregor},
  title = {ABO ‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70037}
}
Kostenlos starten →